CreOSG Expands Global Patent Portfolio for VSV Vaccine Platform... Strengthens Next-Generation Pandemic Preparedness Technology

CreOSG Co., Ltd. (040350) announced on August 6 that it is expanding its global patent portfolio for the proprietary recombinant Vesicular Stomatitis Virus (VSV)-based vaccine platform, SUV-MAP™, strengthening its technological competitiveness in next-generation infectious diseases and future pandemic preparedness.

The company has recently obtained a Canadian patent for its recombinant VSV vector-based Middle East Respiratory Syndrome (MERS) vaccine, developed through its subsidiary, Sumagen Canada Inc. This achievement follows the Saudi Arabian patent granted in March, and demonstrates once again the originality and potential industrial utility of the SUV-MAP™ platform in major global markets.

The company emphasized that this patent not only secures rights to a single MERS vaccine candidate, but also showcases the platform's technological scalability, enabling rapid design and development of various infectious disease vaccines using the same platform.

SUV-MAP™ is a modular platform that uses attenuated recombinant VSV as a vaccine delivery vector. It develops vaccine candidates by incorporating key antigen genes of target viruses into the VSV vector to induce an immune response.

The company explained that utilizing the platform technology increases development efficiency because, unlike conventional approaches where vaccine structures and production processes are newly developed for each emerging disease, the established vector and manufacturing system can be leveraged. The accumulated experience in design, manufacturing, analysis, and quality control can also be applied to the development of diverse infectious disease vaccines, which is a significant advantage.

The newly patented MERS vaccine is a candidate incorporating the MERS-CoV envelope protein antigen into the VSV platform. The company indicated that it has achieved enhanced safety by attenuating the VSV vector via recombinant technology and has secured proprietary technology that increases the delivery and expression efficiency of the target antigen.

The recombinant VSV platform is a proven technology with existing commercialization examples. The rVSV-based Ebola vaccine "ERVEBO® (rVSV-ZEBOV)" has been approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), and has been deployed for epidemic control in Ebola-affected areas in accordance with World Health Organization (WHO) recommendations.

Building on these precedents, CreOSG expects SUV-MAP™ to emerge as a strategic platform for establishing a diverse infectious disease vaccine pipeline well beyond specific vaccine candidates.

Looking ahead, the company plans to expand application of the platform to high-risk infectious diseases such as Ebola, Marburg disease, Nipah virus, Lassa fever, Crimean-Congo Hemorrhagic Fever (CCHF), Severe Fever with Thrombocytopenia Syndrome (SFTS), and Hantavirus infections. The company also explained that, in the event of new pathogens or virus variants, initial research and development can be rapidly advanced by leveraging the existing platform and its development experience.

Currently, the company is building a vaccine pipeline based on the SUV-MAP™ platform targeting HIV, MERS, COVID-19, Hantavirus, and SFTS, and plans to broaden development to include Ebola and Marburg disease as well. Additionally, CreOSG continues to pursue global patents for the VSV-Zika, VSV-MERS, VSV-COVID-19, VSV-Hantavirus, and VSV-SFTS vaccines.

The company assessed that acquiring this Canadian patent has further strengthened the foundation for technology transfer, joint development, and commercialization in major markets such as North America and the Middle East.

A representative from CreOSG stated, "This patent represents an important milestone not only for a specific infectious disease vaccine, but also as proof that SUV-MAP™ is a scalable vaccine platform applicable to a wide range of infectious diseases. We will establish a vaccine development system capable of rapid responses to emerging and re-emerging viruses based on recombinant VSV technology, expand collaborations with global research institutes, pharmaceutical companies, and government agencies, and develop the platform into a world-class infectious disease response solution."

The acquisition of this patent is expected to further enhance the global intellectual property competitiveness of the SUV-MAP™ platform and serve as a catalyst for broadening the foundation for diverse infectious disease vaccine development, technology transfer, and commercialization.

This content was produced with the assistance of AI translation services.